Physician profile
Joseph Mathew
NPI 1225197320
$3,956.77
in general payments reported to CMS, 2019-2025
21 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $607 · 2020: $504 · 2021: $234 · 2022: $625 · 2023: $640 · 2024: $1,021 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,908 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,907.83 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,267.26 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Philips North America LLC | $1,036.49 | 2020-2024 | (Ak6) Vest Therapy, (8874) Incourage |
| Baxter Healthcare | $465.73 | 2019-2024 | Hillrom - Vest System Model 105 Home Care |
| Astrazeneca Pharmaceuticals LP | $390.27 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $183.12 | 2019-2024 | Stiolto Respimat, Spiriva Respimat |
| Genzyme Corporation | $117.47 | 2022-2025 | |
| Mallinckrodt Hospital Products INC. | $114.84 | 2020-2024 | Acthar |
| Sanofi-Aventis U.S. LLC | $78.99 | 2024 | |
| Insmed, INC. | $64.51 | 2024-2025 | Arikayce |
| Amgen INC. | $45.67 | 2021-2024 | Tezspire |
| Paratek Pharmaceuticals, INC. | $32.98 | 2023-2024 | Nuzyra |
| Covidien LP | $21.96 | 2020 | |
| Mylan Specialty L.P. | $18.27 | 2023 | Yupelri |
| United Therapeutics Corporation | $16.75 | 2024 | Tyvaso |
| Kyowa Kirin, INC. | $16.48 | 2024 | Crysvita |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $15.56 | 2020 | |
| Mallinckrodt Enterprises LLC | $15.00 | 2019 | |
| Sunovion Pharmaceuticals INC. | $15.00 | 2019 | |
| Daiichi Sankyo INC. | $14.03 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.00 | 2020 | |
| Shire North American Group INC | $12.39 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.